Literature DB >> 21892180

A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis.

Kari A Sweeney1, Dee N Dao, Michael F Goldberg, Tsungda Hsu, Manjunatha M Venkataswamy, Marcela Henao-Tamayo, Diane Ordway, Rani S Sellers, Paras Jain, Bing Chen, Mei Chen, John Kim, Regy Lukose, John Chan, Ian M Orme, Steven A Porcelli, William R Jacobs.   

Abstract

We report the involvement of an evolutionarily conserved set of mycobacterial genes, the esx-3 region, in evasion of bacterial killing by innate immunity. Whereas high-dose intravenous infections of mice with the rapidly growing mycobacterial species Mycobacterium smegmatis bearing an intact esx-3 locus were rapidly lethal, infection with an M. smegmatis Δesx-3 mutant (here designated as the IKE strain) was controlled and cleared by a MyD88-dependent bactericidal immune response. Introduction of the orthologous Mycobacterium tuberculosis esx-3 genes into the IKE strain resulted in a strain, designated IKEPLUS, that remained susceptible to innate immune killing and was highly attenuated in mice but had a marked ability to stimulate bactericidal immunity against challenge with virulent M. tuberculosis. Analysis of these adaptive immune responses indicated that the highly protective bactericidal immunity elicited by IKEPLUS was dependent on CD4(+) memory T cells and involved a distinct shift in the pattern of cytokine responses by CD4(+) cells. Our results establish a role for the esx-3 locus in promoting mycobacterial virulence and also identify the IKE strain as a potentially powerful candidate vaccine vector for eliciting protective immunity to M. tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21892180      PMCID: PMC3250071          DOI: 10.1038/nm.2420

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  50 in total

Review 1.  Fatal pulmonary infection caused by Mycobacterium smegmetis in an infant.

Authors:  K J Kumar; J Chandra; R N Mandal; R Dutta; N K Jain
Journal:  Indian J Pediatr       Date:  1995 Sep-Oct       Impact factor: 1.967

2.  The 19-kD antigen and protective immunity in a murine model of tuberculosis.

Authors:  V V Yeremeev; I V Lyadova; B V Nikonenko; A S Apt; C Abou-Zeid; J Inwald; D B Young
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

3.  Prolonged toll-like receptor signaling by Mycobacterium tuberculosis and its 19-kilodalton lipoprotein inhibits gamma interferon-induced regulation of selected genes in macrophages.

Authors:  Rish K Pai; Meghan E Pennini; Aaron A R Tobian; David H Canaday; W Henry Boom; Clifford V Harding
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

4.  Acute infection and macrophage subversion by Mycobacterium tuberculosis require a specialized secretion system.

Authors:  Sarah A Stanley; Sridharan Raghavan; William W Hwang; Jeffery S Cox
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-13       Impact factor: 11.205

5.  The temporal expression profile of Mycobacterium tuberculosis infection in mice.

Authors:  Adel M Talaat; Rick Lyons; Susan T Howard; Stephen Albert Johnston
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-18       Impact factor: 11.205

6.  Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature.

Authors:  G A Colditz; T F Brewer; C S Berkey; M E Wilson; E Burdick; H V Fineberg; F Mosteller
Journal:  JAMA       Date:  1994-03-02       Impact factor: 56.272

7.  Genetic requirements for mycobacterial survival during infection.

Authors:  Christopher M Sassetti; Eric J Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

8.  Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis.

Authors:  G G Mahairas; P J Sabo; M J Hickey; D C Singh; C K Stover
Journal:  J Bacteriol       Date:  1996-03       Impact factor: 3.490

9.  Inhibition of major histocompatibility complex II expression and antigen processing in murine alveolar macrophages by Mycobacterium bovis BCG and the 19-kilodalton mycobacterial lipoprotein.

Authors:  Scott A Fulton; Scott M Reba; Rish K Pai; Meghan Pennini; Martha Torres; Clifford V Harding; W Henry Boom
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

10.  Protection against Mycobacterium tuberculosis infection by adoptive immunotherapy. Requirement for T cell-deficient recipients.

Authors:  I M Orme; F M Collins
Journal:  J Exp Med       Date:  1983-07-01       Impact factor: 14.307

View more
  92 in total

1.  Vaccines: Protecting against tuberculosis.

Authors:  Charlotte Harrison
Journal:  Nat Rev Drug Discov       Date:  2011-10-31       Impact factor: 84.694

2.  Tuberculosis vaccine promises sterilizing immunity.

Authors:  Helen McShane; Ann Williams
Journal:  Nat Med       Date:  2011-10-11       Impact factor: 53.440

3.  Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells.

Authors:  Diane J Ordway; Shaobin Shang; Marcela Henao-Tamayo; Andres Obregon-Henao; Laura Nold; Megan Caraway; Crystal A Shanley; Randall J Basaraba; Colleen G Duncan; Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2011-07-27

Review 4.  Tuberculosis vaccine types and timings.

Authors:  Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

5.  cGAS-STING-TBK1-IRF3/7 induced interferon-β contributes to the clearing of non tuberculous mycobacterial infection in mice.

Authors:  Nanthapon Ruangkiattikul; Andreas Nerlich; Ketema Abdissa; Stefan Lienenklaus; Abdulhadi Suwandi; Nina Janze; Kristin Laarmann; Julia Spanier; Ulrich Kalinke; Siegfried Weiss; Ralph Goethe
Journal:  Virulence       Date:  2017-04-19       Impact factor: 5.882

6.  Isocitrate lyase encoding plasmids in BCG cause increased survival in ApoB100-only LDLR-/- mice.

Authors:  Agnes Mira Szabo; Valeria Endresz; Ferenc Somogyvari; Andras Miczak; Ildiko Faludi
Journal:  Mol Biol Rep       Date:  2013-05-08       Impact factor: 2.316

7.  Comparison of the membrane proteome of virulent Mycobacterium tuberculosis and the attenuated Mycobacterium bovis BCG vaccine strain by label-free quantitative proteomics.

Authors:  Harsha P Gunawardena; Meghan E Feltcher; John A Wrobel; Sheng Gu; Miriam Braunstein; Xian Chen
Journal:  J Proteome Res       Date:  2013-10-28       Impact factor: 4.466

Review 8.  ESX secretion systems: mycobacterial evolution to counter host immunity.

Authors:  Matthias I Gröschel; Fadel Sayes; Roxane Simeone; Laleh Majlessi; Roland Brosch
Journal:  Nat Rev Microbiol       Date:  2016-09-26       Impact factor: 60.633

9.  Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.

Authors:  Ming Zhang; Chunsheng Dong; Sidong Xiong
Journal:  Hum Vaccin Immunother       Date:  2016-12-14       Impact factor: 3.452

10.  Enhanced protective efficacy against Mycobacterium tuberculosis afforded by BCG prime-DNA boost regimen in an early challenge mouse model is associated with increased splenic interleukin-2-producing CD4 T-cell frequency post-vaccination.

Authors:  Han Kang; Qin Yuan; Hui Ma; Zhi-Dong Hu; De-Ping Han; Kang Wu; Douglas B Lowrie; Xiao-Yong Fan
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.